BIOMAT Database Logo BIOMAT Database Logo

Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. 1993

M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Department of Pharmacology, Dainippon Pharmaceutical Co., Ltd., Suita/Osaka, Japan.

The pharmacological properties of AD-5423 [2-(4-ethyl-1-piper-azinyl)-4- (4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine] were studied in biochemical and behavioral tests. In vitro, AD-5423 bound preferentially to dopamine (DA)-D2 (Ki, 14.8 nM; cf. haloperidol, 8.79 nM; and clozapine, 149 nM) and serotonin (5-HT)-S2 (Ki, 3.98 nM; cf. haloperidol, 26.8 nM; and clozapine, 8.66 nM) receptors. It displayed low affinity for adrenaline (Ad)-alpha-1 (Ki, 56.3 nM) receptors and was virtually devoid of binding to DA-D1 (Ki, 2870 nM), 5-HT-S3, Ad-alpha-2, Ad-beta, muscarine, tau-aminobutyric acid and benzodiazepine receptors. In addition, AD-5423 was only a weak inhibitor of DA, 5-HT and noradrenaline uptake systems. When administered p.o., AD-5423 (0.3-10 mg/kg) increased brain contents of the DA metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid in mice and rats and the 5-HT metabolite 5-hydroxyindoleacetic acid in mice. Behaviorally, AD-5423 (0.2-2 mg/kg p.o.) decreased exploratory activity in mice, suppressed conditioned avoidance responding and methamphetamine-induced hyperactivity in mice and rats, antagonized apomorphine-induced gnawing in rats and vomiting in dogs and reduced hostile responses in monkeys. In these effects, AD-5423 was more or less equi-potent to haloperidol. However, AD-5423 (10 mg/kg p.o.), unlike haloperidol, did not antagonize SKF38393-induced vacuous oral movements in rats. Head twitches induced by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane in mice and by para-chloroamphetamine in rats were antagonized by AD-5423 at much lower doses (0.5-2 mg/kg p.o.) than those of haloperidol and clozapine.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D010880 Piperidines A family of hexahydropyridines.
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog

Related Publications

M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
February 1988, The Journal of pharmacology and experimental therapeutics,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
August 2010, Pharmacology, biochemistry, and behavior,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition.
February 2003, Bioorganic & medicinal chemistry letters,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties.
January 1992, Clinical neuropharmacology,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent.
February 2005, Bioorganic & medicinal chemistry letters,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands.
November 2003, Bioorganic & medicinal chemistry,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist.
March 1993, The Journal of pharmacology and experimental therapeutics,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone.
January 1987, Psychopharmacology series,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
May 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
M Oka, and Y Noda, and Y Ochi, and K Furukawa, and T Une, and S Kurumiya, and K Hino, and T Karasawa
Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics.
December 1986, Biological psychiatry,
Copied contents to your clipboard!